Adult Dosing
Chronic hepatitis C virus (HCV) genotype 3 infection
- Recommended dose: 60 mg daclatasvir and sofosbuvir PO qd x 12 weeks, with or without food.For specific dosage recommendations for sofosbuvir, refer to the respective prescribing information
NoteDosage modification due to drug interactions- Refer to drug interactions and contraindications for other drugs before coadministration with daclatasvir
- Coadministration with strong CYP3A inhibitors: Decrease dose to 30 mg PO qd using 30 mg tablet Examples of strong CYP3A inhibitors include atazanavir/ritonavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, saquinavir, telithromycin, voriconazole
- Coadministration with moderate CYP3A inducers: Increase dose to 90 mg PO qd using either three 30 mg tablets or one 60 mg and one 30 mg tablet Examples of moderate CYP3A inducers include bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcillin, rifapentine
- Coadministration with strong CYP3A inducers: Daclatasvir is contraindicated
- Dosage reduction for adverse reactions is not recommended
Discontinuation of therapy- If sofosbuvir is permanently discontinued in a patient receiving daclatasvir with sofosbuvir, then daclatasvir should also be discontinued
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
Pregnancy Category: Not rated
Breastfeeding: Safety unknown.
- Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
⬇
